Ventyx Biosciences’ (VTYX) “Neutral” Rating Reiterated at HC Wainwright

Ventyx Biosciences (NASDAQ:VTYX)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $6.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 185.71% from the company’s previous close.

Several other analysts also recently weighed in on VTYX. Canaccord Genuity Group reduced their price objective on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Wells Fargo & Company reduced their target price on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Finally, Oppenheimer restated an “outperform” rating and set a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Ventyx Biosciences Stock Down 2.3 %

NASDAQ VTYX opened at $2.10 on Monday. The stock has a market capitalization of $148.40 million, a PE ratio of -0.90 and a beta of 0.37. The firm has a 50 day moving average of $2.24 and a two-hundred day moving average of $2.80. Ventyx Biosciences has a 52 week low of $1.79 and a 52 week high of $11.48.

Hedge Funds Weigh In On Ventyx Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Palumbo Wealth Management LLC purchased a new position in Ventyx Biosciences in the 3rd quarter valued at $26,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Ventyx Biosciences by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after acquiring an additional 5,310 shares during the period. SG Americas Securities LLC purchased a new position in Ventyx Biosciences during the second quarter worth about $32,000. Intech Investment Management LLC acquired a new stake in Ventyx Biosciences in the third quarter valued at about $42,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after purchasing an additional 7,096 shares in the last quarter. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.